Unilife and Amgen enter US$75m injectable drug delivery systems deal

Published: 24-Feb-2016
Drug Delivery Pharmaceutical

Collaboration includes licensing and master development and supply agreements


Unilife Corporation, a US developer of injectable drug delivery systems, has signed an exclusive agreement with Amgen for a wearable injector device.

The collaboration gives Amgen exclusive rights to Unilife's wearable injectors within certain drug classes for use with some Amgen assets.

Unilife, headquartered in York, PA, has also granted Amgen non-exclusive rights to all of the firm's proprietary delivery systems within the therapeutic areas of oncology, inflammation, bone health, nephrology, cardiovascular and neuroscience.

Amgen made a US$15m payment to Unilife in connection with the exclusivity deal in December 2015. In addition, Unilife is eligible to receive up to $75m. At closing, Amgen paid a nonrefundable $20m licensing fee and purchased a $30m senior secured convertible note from Unilife. Amgen may also purchase up to an additional $25m in senior secured convertible notes over the next two years ($15m in January 2017 and $10m in January 2018).

In addition to these payments, Unilife expects to generate future revenue from the strategic collaboration with Amgen.

'Unilife looks forward to a long-term strategic collaboration with Amgen to drive value for patients, prescribers and payers,' said Ian Hanson, Senior Vice President and General Manager of Unilife's Wearable Injector business unit. 'Unilife is pleased to advance its leadership position in the wearable injectors market to meet growing demand for biologics and other medicines. Our prefilled, pre-assembled and ready-to-inject delivery systems are easy-to-use and enhance patient experience.'

Alison Moore, Senior Vice President of Process Development at Amgen, added: 'One important pillar of Amgen's strategy is to invest in leading drug delivery technologies to more effectively meet the needs of patients suffering from serious illnesses. Unilife continues to develop technology that could provide patients with innovative and meaningful enhancements to drug administration.'

  • Companies:
  • Amgen
See more

You may also like

Drug Delivery

Synaffix enters ADCs agreement with Amgen

Read more
Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments

Trending Articles

  1. You need to be a subscriber to read this article.
    Click here to find out more.
    Merck jumps on the GLP-1 therapeutic bandwagon by licensing Hansoh Pharma's HS-10535 Merck will be responsible for the development, manufacture and commercialisation of the investigational preclinical oral GLP-1 receptor agonist
  2. Theranexus and Exeltis sign commercialisation agreement for neurological disorder-targeting TX01 The therapeutic will be used to target Gaucher and Niemann-Pick type C, with Exeltis attaining the exclusive rights to the marketing and distribution of TX01 across the Europe, South America and the Middle East
  3. Novo Nordisk invests DKK 8.5bn into new Danish modular production site This is the first time this century that Novo Nordisk has invested into its Danish production capabilities, with the site being capable of manufacturing product types within rare disease indications
  4. Bayer's acoramidis recommended for approval by the EMA's CHMP for cardiomyopathy The orally administered transthyretin (TTR) stabiliser is suitable for patients with transthyretin amyloid cardiomyopathy, demonstrating at least a 90% TTR stabilisation capacity and a reduction in cardiovascular-related hospitalisations
  5. Get ahead in the pharmaceutical industry with a Manufacturing Chemist subscription With a Manufacturing Chemist subscription you receive exclusive access to the latest news, technical insights, regulatory updates, and market intelligence

Upcoming event

EMPQ Essentials and Real-World Strategies for Successful Cleanroom Qualifications

16 January 2025 | Virtual See all

You may also like

Drug Delivery

Synaffix enters ADCs agreement with Amgen

Synaffix will be eligible to receive up to $2 billion in payments spanning signature, program nomination and milestone payments
Ingredients

Therapeutic: tezepelumab for asthma

An estimated 2.5 million people around the world are thought to have uncontrolled asthma and many do not respond adequately to currently available preventer medicines
Research & Development

Oxford Nanopore gets cash injection

Biotech company Amgen has announced a £50m (US$66m) equity investment in the UK-based company developing real-time genetic sequencing technology
Media

GlobalData names top 25 global pharma companies by market cap

The performance highlights of the top 25 publicly traded global pharma companies for the year 2017 have been confirmed in the latest research from GlobalData
You need to be a subscriber to read this article.
Click here to find out more.
Media

A precision medicine approach to developing cancer vaccines

Modern anticancer medicines represent a significant improvement on one-size-fits-all chemotherapy, reports Dr Sarah Houlton
Pharmaceutical

Amgen and Daiichi Sankyo to commercialise biosimilars in Japan

The exclusive agreement includes nine biosimilars in late-stage development
Training & Education

Amgen Foundation commits US$4m to bring hands-on biotechnology labs to secondary school students

Amgen Biotech Experience expected to reach more than 150,000 students over the next two years
Subscribe now